May 2000 – The CenterWatch Monthly : Volume 7, Issue 5, May 2000
A Quiet Transformation for Private CROs
Contrary to analyst predictions, small and mid-sized private CROs are finding sponsors increasingly receptive to working with them.
Private CRO success is tied to providing focused therapeutic expertise, niche services and highly personalized service to sponsors.
Latin American Fever
A changing clinical trials market in Latin American may offer a unique opportunity to reach much larger numbers of study subjects.
Though historically it has been a sub-optimal place to conduct clinical research, a changing regulatory environment, a large consumer base, more positive local government perceptions and better-trained study staff make Latin America an attractive new market for clinical trials.
CentreStage Europe: French SMO ProTest Files for Bankruptcy
Just two years after its inception, the French SMO ProTest has been forced to liquidate due to an inability to raise enough venture capital. The demise of ProTest begs the question: Is the European market ready for SMOs? Experts see the situation as both a warning and a learning experience.
Eye On: Hepatitis
CenterWatch has identified a total of 47 treatments and vaccines in the hepatitis pipeline - representing a total of approximately $150 million to $200 million being spent on clinical development. Although there are no treatments of proven benefit for acute viral hepatitis, all five forms of the virus can cause an acute illness, and all five have virulence and induce pathology primarily on the infected liver. Research on treatments for Hepatitis B and C, the most common forms of viral hepatitis, is promising.
- Month in Review
- Opportunities Underway